BCL2L1 and neoplasm: Docetaxel suppresses tumor growth by various mechanisms such as inhibiting microtubule depolymerization [9], interfering with the expression of apoptotic genes (bcl-2 and bcl-xL) [10], suppressing tumor angiogenesis [11], and/or inhibiting cellular signaling pathways [12].